Advancement in monoclonal antibody therapy for multiple myeloma
Mené dans 18 pays sur 522 patients atteints d’un myélome multiple réfractaire ou récidivant, cet essai de phase III évalue la non infériorité, du point de vue de la réponse globale, et la toxicité du daratumumab dispensé par voie sous-cutanée par rapport au daratumumab dispensé par voie intraveineuse (durée médiane de suivi : 7,5 mois)
Novel drug therapies have shifted the paradigm in the management of patients with multiple myeloma. Of the plethora of new therapies available, monoclonal antibodies have gained attention not only by their ability to induce responses in such patients with disease refractory to immunomodulatory drugs and proteasome inhibitors, but also through their synergistic effect when used in combination with standard regimens. Daratumumab, a CD38 monoclonal antibody, is now commonly used after approval by the US Food and Drug Administration for both newly diagnosed and relapsed or refractory multiple myeloma, as monotherapy and in combination with other therapies.